Cure8 research brief
The study identifies epithelial IFN‑I signaling as a driver of barrier failure in anti‑TNF refractory Crohn’s disease and suggests that blocking IFN‑I could be a rescue strategy for patients who do not respond to anti‑TNF biologics.
Clinicians treating anti‑TNF non‑responders, researchers studying IBD therapeutic resistance, and patients on biologic therapy
The authors analyzed human intestinal biopsies, single‑cell RNA sequencing, mouse and patient‑derived organoid models, and tested interventions ex vivo. They found a TNF–IFN‑I signaling interaction that drives epithelial stress and defective repair in anti‑TNF non‑responders.
Low‑dose butyrate reduced IFN‑I genes in responder organoids but did not rescue non‑responder organoids. Treating non‑responder organoids with an anti‑IFN‑I antibody reduced IFN‑I signaling and improved epithelial integrity, suggesting epithelial IFN‑I blockade as a potential rescue strategy.
This study supports considering epithelial IFN‑I gene expression and functional ex vivo testing when evaluating patients who fail anti‑TNF therapy, but the findings come from tissue analyses and organoid/murine models rather than completed clinical trials.
Findings are grounded in biopsies, single‑cell RNA‑seq, murine models, and patient‑derived organoids (structured abstract). Anti‑IFN‑I results are preclinical/ex vivo and do not yet represent tested clinical treatments.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: NIH HHS - DK056008; University of Otago Dean's Bequest Fund; Health Research Council of New Zealand - #22/262; Health Research Council of New Zealand Emerging Researcher Award 2024 - 24/659/A; University of Otago Māori Summer Studentship Scholarship and a University of Otago Māori Masters Scholarship; New Zealand Society of Gastroenterology Janssen Research Fellowship 2023; Healthcare Otago Trust 22HCO-2
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
This study maps cell-level signatures in newly diagnosed pediatric Crohn’s and links them to later severity and responses to anti-TNF treatment, which could help predict which children will respond to biologic therapy...
The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness...
